Other potential anti‐tumor targets include BMV vaccines that induce self‐production of antibodies to attack tumor cells, epidermal growth factor (EGFR) and the basic fibroblast growth factor (BFGF).[218] Genetic modification technology reveals successful introduction of the full‐length mouse BFGF molecule onto E. coil OMVs and their breaking B cell tolerance in the body. This evidence concerns the gene FGF2 and neoplasm.